New AGA guideline ranks the most effective drugs for weight loss

AGA released new evidence-based guidelines strongly recommending patients with obesity use recently approved medications paired with lifestyle changes.

The following medications, paired with healthy eating and regular physical activity, are first-line medical options and result in moderate weight loss as noted as a percentage of body weight (reported as the difference compared to percent weight loss observed in the placebo group).

• Semaglutide (Wegovy®), weight loss percentage: 10.8%
• Phentermine-topiramate ER (Qsymia®), weight loss percentage: 8.5%
• Liraglutide (Saxenda®), weight loss percentage: 4.8%
• Naltrexone-bupropion ER (Contrave®), weight loss percentage: 3.0%

Read the AGA Clinical Guidelines on Pharmacological Interventions for Adults with Obesity for the complete recommendations.

AGA released new evidence-based guidelines strongly recommending patients with obesity use recently approved medications paired with lifestyle changes.

The following medications, paired with healthy eating and regular physical activity, are first-line medical options and result in moderate weight loss as noted as a percentage of body weight (reported as the difference compared to percent weight loss observed in the placebo group).

• Semaglutide (Wegovy®), weight loss percentage: 10.8%
• Phentermine-topiramate ER (Qsymia®), weight loss percentage: 8.5%
• Liraglutide (Saxenda®), weight loss percentage: 4.8%
• Naltrexone-bupropion ER (Contrave®), weight loss percentage: 3.0%

Read the AGA Clinical Guidelines on Pharmacological Interventions for Adults with Obesity for the complete recommendations.

AGA released new evidence-based guidelines strongly recommending patients with obesity use recently approved medications paired with lifestyle changes.

The following medications, paired with healthy eating and regular physical activity, are first-line medical options and result in moderate weight loss as noted as a percentage of body weight (reported as the difference compared to percent weight loss observed in the placebo group).

• Semaglutide (Wegovy®), weight loss percentage: 10.8%
• Phentermine-topiramate ER (Qsymia®), weight loss percentage: 8.5%
• Liraglutide (Saxenda®), weight loss percentage: 4.8%
• Naltrexone-bupropion ER (Contrave®), weight loss percentage: 3.0%

Read the AGA Clinical Guidelines on Pharmacological Interventions for Adults with Obesity for the complete recommendations.